139 related articles for article (PubMed ID: 33667892)
21. Murine Retrovirally-Transduced Bone Marrow Engraftment Models of MLL-Fusion-Driven Acute Myelogenous Leukemias (AML).
Stubbs MC; Krivtsov AV
Curr Protoc Pharmacol; 2017 Sep; 78():14.42.1-14.42.19. PubMed ID: 28892146
[TBL] [Abstract][Full Text] [Related]
22. Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias.
Mullighan CG; Kennedy A; Zhou X; Radtke I; Phillips LA; Shurtleff SA; Downing JR
Leukemia; 2007 Sep; 21(9):2000-9. PubMed ID: 17597811
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of Methyltransferase DOT1L Sensitizes to Sorafenib Treatment AML Cells Irrespective of
Lonetti A; Indio V; Laginestra MA; Tarantino G; Chiarini F; Astolfi A; Bertuccio SN; Martelli AM; Locatelli F; Pession A; Masetti R
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698374
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
25. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.
Somers K; Chudakova DA; Middlemiss SM; Wen VW; Clifton M; Kwek A; Liu B; Mayoh C; Bongers A; Karsa M; Pan S; Cruikshank S; Scandlyn M; Hoang W; Imamura T; Kees UR; Gudkov AV; Chernova OB; Haber M; Norris MD; Henderson MJ
Oncotarget; 2016 Jul; 7(29):46067-46087. PubMed ID: 27317766
[TBL] [Abstract][Full Text] [Related]
26. Decitabine mildly attenuates
Schneider P; Castro PG; Pinhanços SM; Kerstjens M; van Roon EH; Essing AHW; Dolman MEM; Molenaar JJ; Pieters R; Stam RW
EJHaem; 2020 Nov; 1(2):527-536. PubMed ID: 35844991
[No Abstract] [Full Text] [Related]
27. Outcome of allogeneic hematopoietic stem-cell transplantation for adult patients with AML and 11q23/MLL rearrangement (MLL-r AML).
Pigneux A; Labopin M; Maertens J; Cordonnier C; Volin L; Socié G; Blaise D; Craddock C; Milpied N; Bacher U; Malard F; Esteve J; Nagler A; Mohty M;
Leukemia; 2015 Dec; 29(12):2375-81. PubMed ID: 26082270
[TBL] [Abstract][Full Text] [Related]
28. Possible repurposing of pyrvinium pamoate for the treatment of mesothelioma: A pre-clinical assessment.
Barbarino M; Cesari D; Intruglio R; Indovina P; Namagerdi A; Bertolino FM; Bottaro M; Rahmani D; Bellan C; Giordano A
J Cell Physiol; 2018 Sep; 233(9):7391-7401. PubMed ID: 29659015
[TBL] [Abstract][Full Text] [Related]
29. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
30. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
31. Anlotinib suppresses MLL-rearranged acute myeloid leukemia cell growth by inhibiting SETD1A/AKT-mediated DNA damage response.
Chen J; Feng J; Fang Z; Ye J; Chen Q; Chen Q; Chen K; Xiong X; Li G; Song H; Xu B
Am J Transl Res; 2021; 13(3):1494-1504. PubMed ID: 33841673
[TBL] [Abstract][Full Text] [Related]
32. Pyrvinium selectively targets blast phase-chronic myeloid leukemia through inhibition of mitochondrial respiration.
Xiang W; Cheong JK; Ang SH; Teo B; Xu P; Asari K; Sun WT; Than H; Bunte RM; Virshup DM; Chuah C
Oncotarget; 2015 Oct; 6(32):33769-80. PubMed ID: 26378050
[TBL] [Abstract][Full Text] [Related]
33. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
34. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
35. Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus.
Gyárfás T; Wintgens J; Biskup W; Oschlies I; Klapper W; Siebert R; Bens S; Haferlach C; Meisel R; Kuhlen M; Borkhardt A
Mol Cell Pediatr; 2016 Dec; 3(1):30. PubMed ID: 27510896
[TBL] [Abstract][Full Text] [Related]
36. Targeting epigenetic programs in MLL-rearranged leukemias.
Bernt KM; Armstrong SA
Hematology Am Soc Hematol Educ Program; 2011; 2011():354-60. PubMed ID: 22160057
[TBL] [Abstract][Full Text] [Related]
37. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
[TBL] [Abstract][Full Text] [Related]
38. Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5.
Poirel H; Rack K; Delabesse E; Radford-Weiss I; Troussard X; Debert C; Leboeuf D; Bastard C; Picard F; Veil-Buzyn A; Flandrin G; Bernard O; Macintyre E
Blood; 1996 Mar; 87(6):2496-505. PubMed ID: 8630416
[TBL] [Abstract][Full Text] [Related]
39. MLL-AF6 fusion oncogene sequesters AF6 into the nucleus to trigger RAS activation in myeloid leukemia.
Manara E; Baron E; Tregnago C; Aveic S; Bisio V; Bresolin S; Masetti R; Locatelli F; Basso G; Pigazzi M
Blood; 2014 Jul; 124(2):263-72. PubMed ID: 24695851
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic drug screen identifies the histone deacetylase inhibitor NSC3852 as a potential novel drug for the treatment of pediatric acute myeloid leukemia.
Wiggers CRM; Govers AMAP; Lelieveld D; Egan DA; Zwaan CM; Sonneveld E; Coffer PJ; Bartels M
Pediatr Blood Cancer; 2019 Aug; 66(8):e27785. PubMed ID: 31044544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
